Publications

Publications

Filter Results: (208) Arrow Down
Filter Results: (208) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 4 of 208 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • 2023
  • Working Paper

Market Exclusivity and Innovation: Evidence From Antibiotics

By: Edward Kong and Olivia Zhao
The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details
Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States
Related
  • Research Summary

Putting Patients First: Marketing Strategies for Treating HIV in Developing Nations

It is more than mere coincidence that the highest rates of HIV occur in the world’s poorest countries. Of the over 40 million people currently living with HIV, 95 percent are in the developing world. The first half of this paper explores the economics of HIV and... View Details
  • March 1993
  • Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III
Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details
Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States
Related
  • 15 Jan 2008
  • First Look

First Look: January 15, 2008

Incompatible Assumptions: Barriers to Producing Multidisciplinary Knowledge in Communities of Scholarship Authors:Corinne Bendersky and Kathleen L. McGinn Abstract Co-locating knowledge workers from different disciplines may be a necessary but insufficient step to... View Details
Keywords: Martha Lagace
  • March 2002 (Revised May 2002)
  • Case

Genzyme: Engineering the Market for Orphan Drugs

Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Pharmaceutical Industry; Pharmaceutical Industry
Related
  • 05 Sep 2023
  • Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

acid deficiency. When the drug was reformulated with folic acid, it passed its efficacy trials, eventually becoming a multibillion-dollar pharmaceutical that helped thousands of lung cancer patients. How to fail intelligently Edmondson,... View Details
Keywords: by Michael Blanding
  • 15 May 2007
  • First Look

First Look: May 15, 2007

orders placed for delivery tomorrow include more items for planned meals (as opposed to items for general stocking) than orders placed for delivery in the more distant future, and that groceries for planned meals entail more should items... View Details
Keywords: Martha Lagace
  • February 2024
  • Article

Representation and Extrapolation: Evidence from Clinical Trials

By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is more relevant for decision-making by physicians and patients when it... View Details
Keywords: Representation; Racial Disparity; Health Testing and Trials; Race; Equality and Inequality; Innovation and Invention; Pharmaceutical Industry
Related
  • May 2002 (Revised October 2005)
  • Case

Marketing Antidepressants: Prozac and Paxil

By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Related
  • 21 Apr 2009
  • First Look

First Look: April 21, 2009

participation decisions. Based on our experimental results, we suggest preliminary lessons for improving the design of household risk management contracts. Download the paper: http://www.hbs.edu/research/pdf/09-116.pdf Where Is the Pharmacy to the World? International... View Details
Keywords: Martha Lagace
  • December 2005 (Revised October 2006)
  • Case

Pharmacy Service Improvement at CVS (A)

CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems... View Details
Keywords: Information Technology; Performance Improvement; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry; United States
Related
  • Research Summary

Overview

My focus is empirical financial accounting research, with particular interests in governance, valuation, M&A, and short-sellers. All three of my papers to date fall under the broad heading of “alternative governance mechanisms”—studies of how accounting information is... View Details
Keywords: Mergers and Acquisitions; Corporate Governance; Valuation; Law
  • Research Summary

Overview

My focus is empirical financial accounting research, with particular interests in governance, valuation, M&A, and short-sellers. All three of my papers to date fall under the broad heading of “alternative governance mechanisms”—studies of how accounting information is... View Details
Keywords: Mergers and Acquisitions; Corporate Governance; Valuation; Law
  • Research Summary

Clinical Trials as a setting for Health Policy and Management Research

The clinical trial marketplace is in flux. A decade ago, pharmaceutical firms almost exclusively conducted the study of their novel drug compounds within major academic medical centers. But today, industry-sponsored clinical trials are increasingly using community... View Details
  • 25 Jul 2023
  • Research & Ideas

Could a Business Model Help Big Pharma Save Lives and Profit?

low-income countries, instead of zealously guarding it, cutting it off from patients and profits. The licensees then work with local governments and markets while paying the pharmaceutical company for the right to sell View Details
Keywords: by Esther Schrader; Pharmaceutical; Pharmaceutical
  • 10 Oct 2007
  • First Look

First Look: First Look: October 10

Hamermesh, Faculty Chair of the Harvard Business Healthcare Initiative, discuss the barriers to personalized medicine and suggest ways to overcome them. The blockbuster model for developing drugs, the authors point out, is still what most major View Details
Keywords: Martha Lagace
  • 09 May 2024
  • Research & Ideas

Called Back to the Office? How You Benefit from Ideas You Didn't Know You Were Missing

knowledge sharing outside one’s core department. That is one implication of a new study about how knowledge is shared that focuses on academia, but may offer lessons for technology, pharmaceutical development, and other STEM industries.... View Details
Keywords: by Ben Rand
  • August 2024
  • Article

How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?

By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
Keywords: Prescription Drugs; Coupons; Impact; Health Care and Treatment; Markets; Price; Spending; Pharmaceutical Industry; United States
Related
  • 2023
  • Working Paper

Evaluation and Learning in R&D Investment

By: Alexander P. Frankel, Joshua L. Krieger, Danielle Li and Dimitris Papanikolaou
We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach... View Details
Keywords: Research and Development; Forecasting and Prediction; Valuation; Pharmaceutical Industry
Related
  • 02 Aug 2011
  • First Look

First Look: August 2

the world stage. It is a story that holds many important lessons for the current generation of emerging giants seeking to do the same. Book: http://hbr.org/2011/07/the-globe-the-paradox-of-samsungs-rise/ar/1   Working PapersBig BRICs,... View Details
Keywords: Sean Silverthorne

Are you looking for?

→Search All HBS Web